A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

PHASE3CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

January 29, 2014

Primary Completion Date

November 24, 2016

Study Completion Date

November 24, 2016

Conditions
LeiomyomaUterine Hemorrhage
Interventions
DRUG

Ulipristal acetate (UPA)

Ulipristal acetate (UPA) tablet.

DRUG

Placebo

Matching placebo tablet.

Trial Locations (63)

10461

Watson Investigational Site 155, The Bronx

15206

Watson investigational site 142, Pittsburgh

19114

Watson Investigational Site 133, Philadelphia

19611

Watson Investigational Site 105, West Reading

23456

Watson Investigational Site 137, Virginia Beach

27103

Watson Investigational Site 118, Winston-Salem

27408

Watson Investigational Site 128, Greensboro

27612

Watson Investigational Site 146, Raleigh

27713

Watson Investigational Site 126, Durham

28562

Watson Investigational Site 145, New Bern

29201

Watson Investigational Site 153, Columbia

29425

Watson Investigational Site 110, Charleston

29615

Watson Investigational Site 154, Greenville

29910

Watson Investigational Site 136, Bluffton

30328

Watson Investigational Site 103, Sandy Springs

30342

Watson Investigational Site 160, Atlanta

31406

Watson Investigational Site 117, Savannah

32806

Watson Investigational Site 161, Orlando

33027

Watson Investigational Site 135, Miramar

33161

Watson Investigational Site 132, North Miami

33324

Watson Investigational Site 123, Plantation

33409

Watson Investigational Site 101, West Palm Beach

33414

Watson Investigational Site 102, Wellington

33759

Watson Investigational Site 131, Clearwater

34239

Watson Investigational Site 112, Sarasota

37920

Watson Investigational Site 155, Knoxville

44106

Watson Investigational Site 155, Cleveland

44122

Watson Investigational Site 148, Cleveland

45267

Watson Investigational Site 155, Cincinnati

45322

Watson Investigational Site 139, Englewood

46112

Watson Investigational Site 162, Brownsburg

46530

Watson Investigational Site 104, Granger

60173

Watson Investigational Site 119, Schaumburg

61820

Watson Investigational Site 113, Champaign

70001

Watson Investigational Site 130, Metairie

70115

Watson Investigational Site 116, New Orleans

70433

Watson Investigational Site 150, Covington

72205

Watson Investigational Site 155, Little Rock

75035

Watson Investigational Site 114, Frisco

75231

Watson Investigational Site 122, Dallas

77030

Watson Investigational Site 109, Houston

77054

Watson Investigational Site 155, Houston

77598

Watson Investigational Site 129, Webster

78229

Watson Investigational Site 120, San Antonio

80209

Watson Investigational Site 159, Denver

85032

Watson Investigational Site 147, Phoenix

85209

Watson Investigational Site 138, Mesa

85251

Watson Investigational Site 106, Scottsdale

85712

Watson Investigational Site 124, Tucson

87109

Watson Investigational Site 115, Albuquerque

89109

Watson Investigational Site 108, Las Vegas

89128

Watson Investigational Site 107, Las Vegas

90716

Watson Investigational Site 157, Hawaiian Gardens

91436

Watson Investigational Site 155, Encino

91942

Watson Investigational Site 134, La Mesa

92111

Watson Investigational Site 127, San Diego

92114

Watson Investigational Site 151, San Diego

98105

Watson Investigational Site 121, Seattle

08648

Watson Investigational Site 111, Lawrenceville

08057

Watson Investigational Site 158, Moorestown

23507-1627

Watson Investigational Site 152, Norfolk

L8S4L8

Watson Investigational Site 140, Hamilton

K1H7W9

Watson Investigational Site 144, Ottawa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT02147158 - A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas | Biotech Hunter | Biotech Hunter